Enviar artigo por via de e-mail Analgesic activity of the low molecular weight neurotrophin-3 dipeptide mimetic GTS-301
- Autores: Kolik L.G.1, Konstantinopolsky M.A.1, Sazonova N.M.1, Durnev A.D.1, Gudasheva T.A.1
-
Afiliações:
- FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
- Edição: Volume 520, Nº 1 (2025)
- Páginas: 100-103
- Seção: Articles
- URL: https://ter-arkhiv.ru/2686-7389/article/view/682051
- DOI: https://doi.org/10.31857/S2686738925010166
- EDN: https://elibrary.ru/tcgjna
- ID: 682051
Citar
Acesso aberto
Acesso está concedido
Resumo
It was previously shown that the original dipeptide mimetic of the 4th loop neurotrophin-3 (NT-3) hexamethylenediamide bis-(N-monosuccinyl-L-asparaginyl-L-asparagine) (GTS-301), like full-size neurotrophin, predominantly activates the tyrosine kinase receptor TrkC and has a neuroprotective effect in vitro at concentrations of 10-5-10-12 M, as well as after systemic administration on rodents – antidiabetic (0.1 and 0.5 mg/kg) and antidepressant (5 and 10 mg/kg) effects. In this work, the analgesic properties of GTS-301 were identified, which were manifested in the dose range of 0.01-10 mg/kg after acute intraperitoneal injection to rats in the “tail flick” test. Dipeptide GTS-301 increased the threshold of pain response by 20-30% and the effect persisted for at least 24 hours after administration.
Texto integral
Sobre autores
L. Kolik
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Autor responsável pela correspondência
Email: kolik_lg@academpharm.ru
Rússia, Moscow
M. Konstantinopolsky
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Rússia, Moscow
N. Sazonova
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Rússia, Moscow
A. Durnev
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Сorresponding Мember of the RAS
Rússia, MoscowT. Gudasheva
FSBSI “Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies”
Email: kolik_lg@academpharm.ru
Сorresponding Мember of the RAS
Rússia, MoscowBibliografia
- Hohn A., Leibrock J., Bailey K., et al. // Nature. 1990. V. 344. P. 339–341.
- Rosenthal A., Goeddel D.V., Nguyen T., et al. // Neuron. 1990. V. 4. P. 767–773.
- Siuciak J. A., Altar A., Wiegand S. J., et al. // Brain Res. 1994. V. 633, № 1–2. P. 326–330.
- Malcangio M., Garrett N. E., Cruwys S., et al. // J. Neurosci. 1997. V. 17. № 21. P. 8459.
- Watanabe M., Endo Y., Kimoto K., et al. // Neurosci. Lett. 2000. V. 1–2. № 282. P. 61–64.
- Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W., et al. // J. Neurosci. 2005. V. 25. № 3. P. 758–767.
- Gudasheva T.A., Povarnina P.Y., Tarasiuk A.V., et al. // Med Res Rev. 2021. V. 41. № 5. P. 2746-2774. doi: 10.1002/med.21721.
- Гудашева Т.А., Сазонова Н.М., Тарасюк А.В., и др. // ДАН. 2022. Т. 505. № 1. С. 303-309.
- Ягубова С.С., Чернышевская М.А., Островская Р.У., и др. // ДАН. 2023. Т. 512.
- Hardy J.D., Wolff H.G. and Goodell H. // J Clin Invest. 1940. V. 19. P.649–657.
- Bannon A.W., Malmberg A.B. // Curr Protoc Neurosci. 2007. Chapter 8:Unit 8.9.
- Douglas D.K. and Carstens E. // J Neurophysiol. 1997. V. 77. P. 611–620.
- Maisonpierre P.C., Belluscio L., Friedman B., et al. // Neuron. 1990. V. 5. P. 501–509.
- Ernfors P., Rosario C.M., Merlio J.P., et al. // Brain Res. Mol. Brain Res. 1993. V.17. P. 217–226.
- Гудашева Т.А., Константинопольский М.А., Тарасюк А.В., и др. // ДАН. 2019. Т. 485. № 3. С. 366–369.
- Helgren M.E, Cliffer K.D., Torrento K., et al. // J. Neurosci. 1997. V. 17. P. 372–382.
- Sahenk Z., Nagaraja H.N., McCracken B.S., et al. // Neurology. 2005. V. 65. P. 681–689.
- Степанова О.В., Воронова А.Д., Чадин А.В., и др. // Клеточные технологии в биологии и медицине. 2022. Т. 1. С. 3–8.
Arquivos suplementares
